Ibrutinib

Recent Results in Cancer Research

Volumn 201, Issue , 2014, Pages 259-267

  Schwarzbich, Mark Alexander ^a   Witzens Harig, Matthias ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; IBRUTINIB; PROTEIN KINASE SYK; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; DIARRHEA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; EDEMA; ENZYME INHIBITION; FATIGUE; FOLLICULAR LYMPHOMA; HUMAN; IC50; LARGE CELL LYMPHOMA; LYMPHOCYTOSIS; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; NAUSEA; NONHUMAN; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PHOSPHORYLATION; RASH; SIGNAL TRANSDUCTION; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; B LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; PATHOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES;

EID: 84906932051     PISSN: 00800015     EISSN: 21976767     Source Type: Book Series    
DOI: 10.1007/978-3-642-54490-3_17     Document Type: Article

References (35)

1. Advani RH et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31(1):88–94
2. Bruton OC et al (1952) Absence of serum gamma globulins. AMA Am J Dis Child. 84(5):632–636
3. Burger JA et al (2012) The BTK inhibitor ibrutinib (PCI-32765) in combination with Rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia. In: Blood 120:Abstract 187
4. Burger JA (2013) Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 121(9):1501–1509
5. Byrd JC et al (2012) The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II Study. Blood 120:Abstract 189
6. Chang BY et al (2011) The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther 13(4):R115
7. Cheson BD et al (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 30(23):2820–2822
8. Chiorazzi N et al (2005) Chronic lymphocytic leukemia. N Engl J Med 352(8):804–815
9. Dasmahapatra G et al (2013) The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 161(1):43–56
10. Davis RE et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88–92
11. de Gorter DJ et al (2007) Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26(1):93–104
12. de Rooij MF et al (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptorand chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590–2594
13. Di Paolo JA et al (2011) Specific BTK inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7(1):41–50
14. Dühren-von Minden M et al (2012) Chronic lymphocytic leukaemia is driven by antigenindependent cell-autonomous signalling. Nature 489(7415):309–312
15. Farooqui M et al (2012) 1789 ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. Blood 120:Abstract 1789
16. Fowler NH (2012) The Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood 120:Abstract 156
17. Herman SE et al (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23):6287–6296
18. Honigberg LA et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29):13075–13080
19. Jaglowski SM, Jones JA, Flynn JM et al (2012) A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol 30:(suppl: Abstr 6508)
20. Janeway et al (2005) Immunobiology, 6th edn. Garland science Publishing, New York Liu J et al (2006) Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 108(8):2596–2603
21. O’Brien SM et al (2012) Combination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II study. J Clin Oncol 30:(suppl: Abstr 6515)
22. Ortolano S et al (2006) Roles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur J Immunol 36(5):1285–1295
23. Pan Z et al (2007) Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem 2(1):58–61
24. Ponader S et al (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182–1189
25. Quek LS et al (1998) A role for Bruton’s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 8(20):1137–1140
26. Rushworth SA et al (2013) BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-jB. Cell Signal 25(1):106–112
27. Satterthwaite AB et al (2000) The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 175:120–127
28. Schwamb J et al (2012) B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 120(19):3978–3985
29. Stevenson FK et al (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118(16):4313–4320
30. Tai YT et al (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120(9):1877–1887
31. Vij R et al (2012) Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM). Blood 120:Abstract 4039
32. Wang M et al (2012) Interim results of an international, multicenter, phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up. Blood 120:(Abstract 904)
33. Wilson WH (2012) The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 120:(Abstract 686)
34. Woyach JA et al (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6):1175–1184
35. Yang Y et al (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6, 19):723–737